
A day with Ryker
Hear about the daily routine for Ryker, who was diagnosed with SMA Type 1, and the philosophy of gratitude that his mother has embraced.
Navigating life with SMA
Navigating life with SMA
You will encounter new opportunities and different challenges every day when living with spinal muscular atrophy (SMA), even after treatment. Check out these tips and ideas from caregivers to help you get through each day with more confidence.
Hear about the daily routine for Ryker, who was diagnosed with SMA Type 1, and the philosophy of gratitude that his mother has embraced.
When Slade was diagnosed with SMA, his parents knew they would have to find a care routine that worked for their family. Hear how his parents stick to a schedule to set Slade up for success.
The times when children are proud of themselves are heartwarming moments for parents. Watch Natalie’s parents talk about one such moment and the impact it had on their family.
For a child with SMA, finding activities the whole family enjoys can sometimes be challenging. Check out these caregiver-suggested fun family activities for in and out of the home.
Families living with SMA need to isolate when flu season hits or when an illness is affecting the community. Hear from caregivers about the challenges of staying home and their advice on staying connected with others.
From a birthday party to standing up with a little help, check out special moments that children are experiencing.
Watch the videos
What is the most important information I should know about
ZOLGENSMA?
What is the most important information I should know about ZOLGENSMA?
What should I watch for before and after infusion with ZOLGENSMA?
What do I need to know about vaccinations and ZOLGENSMA?
Do I need to take precautions with the patient’s bodily waste?
What are the possible or likely side effects of ZOLGENSMA?
What is ZOLGENSMA?
ZOLGENSMA is a prescription gene therapy used to treat children less than 2 years old with spinal muscular atrophy (SMA). ZOLGENSMA is given as a one-time infusion into a vein. ZOLGENSMA was not evaluated in patients with advanced SMA.
The safety information provided here is not comprehensive. Talk to the patient’s doctor about any side effects that bother the patient or that don’t go away.
You are encouraged to report suspected side effects by contacting the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch, or Novartis Gene Therapies, Inc. at 833-828-3947.
Please see the Full Prescribing Information.